Radiopharm Theranostics Toekomstige groei
Future criteriumcontroles 0/6
Radiopharm Theranostics is forecast to grow earnings and revenue by 28.9% and 51.3% per annum respectively while EPS is expected to decline by 19% per annum.
Belangrijke informatie
28.9%
Groei van de winst
-19.0%
Groei van de winst per aandeel
| Biotechs winstgroei | 15.2% |
| Inkomstengroei | 51.3% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 15 Oct 2024 |
Recente toekomstige groei-updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 6/30/2027 | 85 | -12 | -10 | -6 | 2 |
| 6/30/2026 | 21 | -36 | -42 | -39 | 3 |
| 6/30/2025 | N/A | -53 | -58 | -55 | 3 |
| 6/30/2024 | 2 | -48 | -23 | -23 | N/A |
| 3/31/2024 | 4 | -47 | -24 | -23 | N/A |
| 12/31/2023 | 6 | -47 | -24 | -23 | N/A |
| 9/30/2023 | 6 | -41 | -25 | -23 | N/A |
| 6/30/2023 | 6 | -35 | -25 | -23 | N/A |
| 3/31/2023 | 5 | -30 | -21 | -20 | N/A |
| 12/31/2022 | 4 | -26 | -18 | -17 | N/A |
| 9/30/2022 | 2 | -28 | -28 | -14 | N/A |
| 6/30/2022 | N/A | -30 | -38 | -10 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: RAD is forecast to remain unprofitable over the next 3 years.
Winst versus markt: RAD is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: RAD is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: RAD is forecast to have no revenue next year.
Hoge groei-inkomsten: RAD is forecast to have no revenue next year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if RAD's Return on Equity is forecast to be high in 3 years time